Reuter U, Ehrlich M, Gendolla A, et al. Erenumab versus topiramate for the prevention of migraine—a randomized, double-blind, active-controlled phase 4 trial. Cephalagia. 2022;42(2):108-118. doi:10.1177/03331024211053571
For the treatment and prevention of episodes, erenumab was found to have a higher tolerability versus topiramte among patients. The results from the HER-MES trial, funded by Novartis, were published in Cephalagia, a journal published monthly on behalf of the International Headache Society.